Overview

Sargramostim Use in COVID-19 to Recover Patient Health

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to understand if the study drug, also called sargramostim or Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This study will also help researchers understand if inhaled sargramostim can help prevent visits to the emergency room or hospitalization, or death.
Phase:
Phase 2
Details
Lead Sponsor:
Partner Therapeutics, Inc.
Collaborator:
United States Department of Defense
Treatments:
Sargramostim